DiaMedica Therapeutics Inc. Share Price

DiaMedica Therapeutics Inc. Share Price

NASDAQ: DMAC | Small Cap
$9.44
-$0.38 (-3.87%) Last updated on 29 Oct, 2026 | 23:58 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

DiaMedica Therapeutics Inc. Stock Performance

Open
$9.88
Prev. Close
$9.82
Circuit Range
N/A
Day Range
$9.46 - $9.93
Year Range
$5.28 - $10.36
Volume
4,875
Average Traded
$9.77

DiaMedica Therapeutics Inc. Share Price Today

As of 30 October 2026, DiaMedica Therapeutics Inc.'s share price is $9.44. The stock opened at $9.88, compared to its previous close of $9.82. During today's trading session, DiaMedica Therapeutics Inc.'s share price traded between $9.46 and $9.93, with an average price of $9.70. Over the past 52 weeks, the stock has recorded a high of $10.36 and a low of $5.28. In terms of performance, DiaMedica Therapeutics Inc.'s share price has risen by 56.55% over the last six months and is up 33.90% on a year-on-year basis.

DiaMedica Therapeutics Inc. Share Price Chart

Line chart of the DiaMedica Therapeutics Inc. price trend over the selected period. The price fell overall, ranging from 9.44 to 9.93, ending at 9.44.
$9.46$9.93
L
Show Current Price
H

DiaMedica Therapeutics Inc. Stock Fundamentals & Key Indicators

Market Cap
$443.50M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.70
Revenue (TTM)
$0.00
Return On Equity (TTM)
-97.88%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-30.39%

DiaMedica Therapeutics Inc. Quarterly Profit & Loss

All figures in USD

ParticularsJun 2025Sep 2025Dec 2025Mar 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$7.70-$8.62-$8.71-$10.04
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-11.95%-1.04%-15.27%

DiaMedica Therapeutics Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$13.68-$19.38-$24.43-$32.74
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-41.67%-26.06%-34.02%

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$8.25
$9.46
+13.57%
Sep 2026
$6.31
$8.33
+23.59%
Aug 2026
$6.35
$6.74
+6.65%
Jul 2026
$7.14
$6.32
-10.61%
Jun 2026
$5.94
$7.07
+17.83%
May 2026
$5.93
$6.00
-0.50%
Apr 2026
$6.80
$6.03
-10.93%
Mar 2026
$7.82
$6.77
-14.74%
Feb 2026
$8.15
$7.94
-1.37%
Jan 2026
$7.81
$8.05
+1.00%
Dec 2025
$8.43
$7.97
-7.54%
Nov 2025
$7.06
$8.62
+22.27%

DMAC Share Price FAQs